Joint Lab Collaboration Unique Joint Lab with Institut Pasteur positions TheraVectys to jointly develop and license immunotherapy and vaccine candidates, enabling faster go-to-market through shared expertise and resources.

Licensing Vector Platform Proprietary lentiviral vector platform with a robust transfection mechanism offers licensing or co-development opportunities for pharma and biotech partners pursuing cancer or infectious disease vaccines, reducing development timelines.

Funding Momentum Recent funding of $20 million demonstrates investor validation and runway for collaboration-focused programs; target partners can propose multi-year co-development or strategic licensing deals aligned with the pipeline.

US Market Access Operational presence in Paris and the United States provides a bridge for cross-border clinical development, regulatory engagement, and potential manufacturing or partner onboarding in key markets.

Specialized Services Small team with an established pipeline and access to Institut Pasteur virology expertise suggests TheraVectys can serve as a specialized vector design, preclinical testing, and early-stage development partner or CRO for immunotherapy projects.